Ozempic maker Novo Nordisk buys Irish drug manufacturing plant in €85m deal
Danish weight loss and diabetes specialist is looking to develop a tablet form of its blockbuster obesity treatments
Alkermes
Science Foundation Ireland making a real difference for society and the economy
SFI has provided €40m in funding to projects tackling challenges in healthcare, climate change and financial services
Cork-based industrial energy company EM3 taken over by Calor owner
SHV Energy acquires majority stake in Charleville-headquartered company
UDG reinstates dividend, guidance despite ongoing Covid-19 uncertainty
Company says third quarter saw drop in revenue as restrictions hit business
Alkermes reports 30% rise in sales of key drug
Company pulls full-year guidance on coronavirus disruption to healthcare systems
Irish drug firm Alkermes sees revenues rise 15% in Q4
Company reports 21% rise in sales to $1.09bn and reduced losses in 2018
UDG Healthcare appoints two non-executive directors to board
Peter Chambré and Shane Cooke to take up roles with services provider on February 1st
Alkermes’ depression treatment fails to get FDA panel backing
Advisory panel votes down opioid-based drug on concerns over safety and efficacy
Alkermes secures US watchdog U-turn on depression drug
Food and Drug Administration accepts filing from Irish pharma group fortnight after refusal
Twice bitten, once shy: Alkermes can’t talk up its depression drug
Cantillon: After two failed trials, Irish biotech company’s product fails to get FDA approval
Alkermes shares dive 22% as FDA refuses to review drug
US regulator says more clinical trials needed before considering Irish drug group’s depression treatment
Losses dip slightly at Alkermes to $72.6m
Dublin-headquartered biopharma company saw rise in revenues for quarter to $191.8m
Alkermes executives take a hit on pay package
Irish-domiciled biopharma group reported 31% rise in sales last year
Packed schedule this year for Great Place to Work Institute
Onsite events offer a first-hand view of efforts organisations make to improve the employee experience
Roscommon safe as boundary review recommends no change
Proposal to move 30 sq km of the south county into Co Westmeath rejected by review
All of Roscommon will remain Roscommon, insists Naughten
‘We will not be proceeding with this land grab,’ says Minister of plan for Athlone area
Alkermes loss rises to $77m in first quarter
Biopharma company reports sales of $156 million, down from $161 million in 2015
Roscommon unites against Westmeath ‘invaders’
Government’s plan to revise border sparks opposition across the county and abroad
Alkermes wins FDA approval for new schizophrenia drug
Shares dip as analysts says initial take-up of Irish group’s drug could be slow at first
Alkermes raises full year forecasts as it prepares new drug launch
Company gears up for new schizophrenia drug Aristada as opioid/alcohol therapy Vivitrol beats expectations
Alkermes looks to schizophrenia drug approval as sales jump 24%
Heavy investment in R&D and set-up costs for new therapies push biopharma group to $30.6m loss
Drug tech firm Alkermes bullish despite reporting full-year loss
Company drops development of new pain therapy after missing targets in Phase 1 trial
Irish VC Fountain wins in $525m Parkinson’s drug deal
Alkermes spinoff also delivers dividend for drug technology group
European healthcare firms hit by US tax threat
Shares in US pharmacy Walgreens also hit as it passes up opportunity for Swiss base
Ronan finds tenants for most of vacant space in Connaught House
Apollo Aviation will move to top floor of block previously occupied by Anglo
Alkermes prefers independence and opts out of takeover trend
Dublin-based pharma group says it’s not in line for takeover driven by Ireland’s low tax regime
Alkermes shares surge as trials prove potential for new schizophrenia drug
Company will seek US marketing approval for long-acting injectible aripiprazole lauroxil
Alkermes beats forecasts as it delivers record revenues for 2013
Biopharma group bullish on prospects for pipeline and existing portfolio this year
Jazz Pharmaceuticals invests €50m in manufacturing plant
Athlone project will create 50 high-skilled full-time jobs when completed by 2016.
Over 600 new jobs as firms announce expansion plans
Centra, Rossport Pharmaceutical and Alexion among firms planning expansion
Alkermes’s key strength is potent pharma pipeline
An inspired approach to clinical trial data is fuelling the firm’s assault on central nervous system ailments
Alkermes hosts gathering of US investors
Group of investment firms looking at investment opportunities in Europe
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices